Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Q4 2024 Management View CEO Herriot Tabuteau highlighted that Axsome has expanded its CNS portfolio to include three commercial products and three late-stage pipeline candidates. The company aims to ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Auvelity is approved for the treatment of adults with major depressive disorder (“MDD”). It is the first approved drug in Axsome’s portfolio. Auvelity was launched in the United States in 2022.

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) resolving all patent ...

Shares of Axsome Therapeutics ( AXSM -0.40%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.